$-0.81 EPS Expected for Summit Therapeutics plc (SMMT)

March 15, 2018 - By Kurt Siggers

 $ 0.81 EPS Expected for Summit Therapeutics plc (SMMT)

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.81 EPS on April, 4.They anticipate $0.31 EPS change or 62.00 % from last quarter’s $-0.5 EPS. After having $-0.20 EPS previously, Summit Therapeutics plc’s analysts see 305.00 % EPS growth. The stock decreased 0.72% or $0.1 during the last trading session, reaching $13.8. About 26,662 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since March 15, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 8 analysts covering Summit Therapeutic (NASDAQ:SMMT), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Summit Therapeutic had 13 analyst reports since August 19, 2015 according to SRatingsIntel. H.C. Wainwright initiated the shares of SMMT in report on Friday, September 16 with “Buy” rating. Zacks downgraded the stock to “Hold” rating in Tuesday, September 1 report. The firm earned “Buy” rating on Thursday, July 6 by H.C. Wainwright. The stock has “Buy” rating by Oppenheimer on Thursday, June 22. The stock of Summit Therapeutics plc (NASDAQ:SMMT) earned “Buy” rating by Canaccord Genuity on Thursday, June 15. H.C. Wainwright reinitiated the stock with “Buy” rating in Friday, December 1 report. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, March 6. The company was maintained on Wednesday, August 19 by Oppenheimer. The firm earned “Buy” rating on Tuesday, June 21 by Janney Capital. The company was maintained on Wednesday, November 16 by RBC Capital Markets.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $200.97 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Quotes.Wsj.com which released: “Summit Therapeutics PLC ADR SMMT (US: Nasdaq)” on February 13, 2011. Also Marketwatch.com published the news titled: “Summit Therapeutics PLC ADR” on June 26, 2016. Marketwatch.com‘s news article titled: “Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta” with publication date: October 04, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: